Kringle Pharma, Inc.
4884.T · JPX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.20 | 0.27 | -0.12 | 0.66 |
| FCF Yield | 0.00% | 0.00% | 0.00% | 0.00% |
| EV / EBITDA | -8.74 | -18.96 | -15.72 | -18.11 |
| Quality | ||||
| ROIC | -8.68% | -11.05% | -14.04% | -8.76% |
| Gross Margin | 0.00% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | – | – | – | – |
| Growth | ||||
| Revenue 3-Year CAGR | 1.59% | -39.74% | -38.52% | -35.54% |
| Free Cash Flow Growth | 0.00% | 0.00% | 0.00% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | 9.18 | 7.20 | 4.20 | 9.90 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 298.20 | 247.97 | 172.09 | 355.06 |